BAX : Summary for Baxter International Inc. Commo - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Baxter International Inc. (BAX)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
46.23 -0.34 (-0.73%)
At close: 4:01PM EST
People also watch
BDX CAH ABT BCR MDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 46.57
Open 46.70
Bid 0.00 x
Ask 0.00 x
Day's Range 46.20 - 47.40
52 Week Range 35.42 - 50.16
Volume 3,541,177
Avg. Volume 3,982,109
Market Cap 25.15B
Beta 0.68
PE Ratio (TTM) 5.18
EPS (TTM) 8.93
Earnings Date Feb 1, 2017
Dividend & Yield 0.52 (1.12%)
Ex-Dividend Date N/A
1y Target Est 52.58
Trade prices are not sourced from all markets
  • Baxter (BAX): Sluggish Macro Environment Mars Prospects
    Zacks 4 days ago

    Baxter (BAX): Sluggish Macro Environment Mars Prospects

    On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

  • Reuters 10 days ago

    Baxter to pay $18 mln over mold at North Carolina plant

    Baxter International has agreed to pay $18 million to resolve its criminal and civil liability over claims its unit ignored mold in air filters at a plant where sterile intravenous solutions were made, the U.S. Justice Department said on Thursday. The resolution includes a deferred prosecution agreement and penalties and forfeiture totaling $16 million and a civil settlement under the False Claims Act with the federal government totaling approximately $2.158 million, the Justice Department said in a statement. The government charged that managers at Baxter Healthcare Corp's North Cove plant in Marion, North Carolina, ignored an employee's warning that mold was found in air filters in the ceiling of the room where sterile intravenous solutions were manufactured, the statement said.

  • Baxter International, Inc. – Value Analysis (NYSE:BAX) : January 11, 2017
    Capital Cube 11 days ago

    Baxter International, Inc. – Value Analysis (NYSE:BAX) : January 11, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Baxter International, Inc. a score of 50. Our analysis is based on comparing Baxter International, Inc. with the following peers – Cardinal Health, Inc., Boston Scientific Corporation, Stryker Corporation, Zimmer Biomet Holdings, Inc., Becton, Dickinson and Company, Halozyme Therapeutics, Inc., C. R. Bard, Inc., Thermo Fisher Scientific ... Read more (Read more...)

  • GuruFocus.com 12 days ago

    Bill Nygren's Oakmark Fund Commentary: Fourth Quarter 2016

    Review of market and holdings

  • Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : BAX-US : January 10, 2017
    Capital Cube 12 days ago

    Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : BAX-US : January 10, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Baxter International, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Is Baxter Poised to Counter Low Cyclophosphamide Sales?
    Zacks 23 days ago

    Is Baxter Poised to Counter Low Cyclophosphamide Sales?

    On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

  • Boston Scientific Down on Risks; Innovations Raise Hope
    Zacks 26 days ago

    Boston Scientific Down on Risks; Innovations Raise Hope

    On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

  • Market Realist 27 days ago

    Financial Metrics of Baxter’s Acquisition of Claris Injectables

    The injectables business of Claris Lifesciences comprises 70.0%–80.0% of its total sales. Claris plans to repatriate about 85.0% of the generated funds to its shareholders.

  • Market Realist last month

    Baxter Advances Portfolio with Acquisition of Claris Injectables

    Through the acquisition of Claris Injectables, Baxter International aims to accelerate its strategy to become a leader in the global injectables market.

  • Market Realist last month

    What Do Analysts Recommend for Baxter International?

    On December 15, 2016, Baxter International (BAX) announced the acquisition of Claris Injectables, a subsidiary of Claris Lifesciences, for $625.0 million.